Investigational drug · Phase 3
Investigational Influenza Vaccine
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019).
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
0 still active
All registered trials
196
Any phase or sponsor naming "Investigational Influenza Vaccine"
First trial start
2023
Dec 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Investigational Influenza Vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza
- COVID-19
- COVID-19 (Coronavirus Disease 2019)
- SARS-CoV-2
- Influenza,Human
Approved drugs for the same conditions: COVID-19 · Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Investigational Influenza Vaccine" as an intervention, largest first.
- Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.Pivotal-lookingCompleted
SeqirusIndustry
NCT01964989 · 10,644 participants · Start Nov 2013 · Primary completion Oct 2015
Drug: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV); Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV) · For: Influenza Virus
Sites: Chandler, Arizona; Harrisburg, Arkansas; Anaheim, California · 167 sites in all
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.Pivotal-lookingCompleted
BioNTech SEIndustry
NCT06178991 · 8,795 participants · Start Dec 20, 2023 · Primary completion Nov 26, 2024
Drug: Influenza and COVID-19 Combination A; Licensed influenza vaccine and 4 more · For: Influenza; COVID-19
Sites: Athens, Alabama; Birmingham, Alabama; Mobile, Alabama · 106 sites in all
- The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and OlderPivotal-lookingCompleted
SeqirusIndustry
NCT06015282 · 7,741 participants · Start Nov 3, 2023 · Primary completion Mar 5, 2024
Drug: Investigational aQIVc; licensed QIVr and 1 more · For: Influenza, Human
Sites: Tempe, Arizona; Little Rock, Arkansas; Huntington Beach, California · 96 sites in all
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza InfectionPivotal-lookingCompleted
Alachua Government Services, Inc.Industry
NCT00800605 · 7,250 participants · Start Dec 2008 · Primary completion May 2009
Drug: Vero cell-derived, trivalent, seasonal influenza vaccine; Placebo: Phosphate-buffered saline · For: Influenza
Sites: Tucson, Arizona; Sacramento, California; San Diego, California · 36 sites in all
- Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of AgePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01051661 · 6,154 participants · Start Feb 12, 2010 · Primary completion Aug 31, 2011
Drug: GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations); GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations) and 1 more · For: Influenza
Sites: Kippa-Ring, Australia; Carlton, Australia; Florianópolis, Brazil · 17 sites in all
Novartis VaccinesNovartis (NVS)
NCT01346592 · 6,104 participants · Start Apr 2011 · Primary completion Jul 2012
Drug: Trivalent split influenza vaccine (TIV); MF59-adjuvanted trivalent influenza vaccine (aTIV) and 1 more · For: Influenza Disease
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Cuidad Automa de Beunos Aires, Argentina · 34 sites in all
- Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza VaccinePivotal-lookingStatus unknown
Changchun BCHT Biotechnology Co.Industry
NCT06280144 · 6,080 participants (planned) · Start Sep 22, 2023 · Primary completion Jun 30, 2024
Drug: Influenza Vaccine, Live, Nasal, Freeze-dried · For: Influenza Prevention
Sites: Chifeng, China
- Phase IV Clinical Trial of an Inactivated Influenza Split VaccinePivotal-lookingCompleted
Hualan Biological Engineering, Inc.Industry
NCT01511744 · 6,000 participants · Start Nov 2011 · Primary completion Nov 2011
Drug: Inactivated influenza split vaccine · For: Human Influenza
Sites: Zhengzhou, China
- Direct and Indirect Protection by Influenza Vaccine Given to Children in IndiaPivotal-lookingCompleted
Wayne Sullender, M.D.Academic, hospital or other
NCT00934245 · 4,598 participants · Start Sep 2009 · Primary completion Jul 2012
Drug: Inactivated Trivalent Influenza Vaccine; Inactivated polio vaccine (IPV) · For: Influenza
Sites: Ballabgarh, India
- Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 YearsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00616928 · 4,561 participants · Start Jan 23, 2008 · Primary completion Oct 15, 2008
Drug: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted; Placebo · For: Influenza
Sites: Huntsville, Alabama; Phoenix, Arizona; Anaheim, California · 40 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Influenza
- GP681Phase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- GP681 SimulantPhase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- BRC-201TG-1000, Pixavir MarboxilPhase 31 trial
Boryung Biopharma Co., Ltd. · Influenza
- mRNA-1018-H5Phase 31 trial
Moderna · Influenza
- Fluzone QudrivalentPhase 22 trials
Sanofi · Healthy Volunteers, Influenza Immunization, Influenza
- TRX-100Phase 22 trials
Traws Pharma, Inc. · Influenza
- ApomivirFE-L-APO, drug substancePhase 21 trial
Far East Bio-Tec Co., Ltd · Influenza
- OVX836Phase 21 trial
Osivax · Influenza
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.